{"preliminary_commentary":{"by_channel":{"x_thread":25,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04489771\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["belzutifan"]],"indication":"advanced clear cell renal cell carcinoma","name":"LITESPARK-013","nct_id":"NCT04489771","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=litespark-013-nct04489771. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1950,"size":"deep","size_rule":"Deep: 301+ verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Participants receive 200 mg of belzutifan by oral administration, once a day (QD), until disease progression or discontinuation.","label":"Belzutifan 200 mg","type":"EXPERIMENTAL"},{"description":"Participants receive 120 mg of belzutifan by oral administration, QD, until disease progression or discontinuation.","label":"Belzutifan 120 mg","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-08-25","type":"ACTUAL"},"conditions":["Carcinoma, Renal Cell"],"enrollment":{"count":154,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Belzutifan","otherNames":["MK-6482","PT2977","WELIREG™"],"type":"DRUG"}],"last_update":"2026-09-24","lead_sponsor":"Merck Sharp & Dohme LLC","official_title":"Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma","overall_status":"COMPLETED","phases":["PHASE2"],"primary_completion_date":{"date":"2023-02-10","type":"ACTUAL"},"primary_outcomes":[{"measure":"Objective Response Rate (ORR) Per Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1) as Assessed by Blinded Independent Central Review (BICR)","timeFrame":"Up to approximately 27 months"}],"references":[{"citation":"Agarwal N, Brugarolas J, Ghatalia P, George S, Haanen JB, Gurney H, Ravilla R, Van der Veldt A, Beuselinck B, Pokataev I, Suelmann BBM, Tuthill MH, Vaena D, Zagouri F, Wu J, Perini RF, Liu Y, Merchan J, Atkins MB. Randomized phase II dose comparison LITESPARK-013 study of belzutifan in patients with advanced clear cell renal cell carcinoma. Ann Oncol. 2024 Dec;35(12):1148-1156. doi: 10.1016/j.annonc.2024.08.2338. Epub 2024 Sep 2.","pmid":"39233312","type":"RESULT"}],"start_date":{"date":"2020-09-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)","url":"https://clinicaltrials.gov/study/NCT04489771"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/litespark-013-nct04489771"}